EA202190530A1 - Агонистические антитела к cd200r и их применение - Google Patents

Агонистические антитела к cd200r и их применение

Info

Publication number
EA202190530A1
EA202190530A1 EA202190530A EA202190530A EA202190530A1 EA 202190530 A1 EA202190530 A1 EA 202190530A1 EA 202190530 A EA202190530 A EA 202190530A EA 202190530 A EA202190530 A EA 202190530A EA 202190530 A1 EA202190530 A1 EA 202190530A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cd200r
application
agonistic antibodies
gvhd
ibd
Prior art date
Application number
EA202190530A
Other languages
English (en)
Inventor
Стивен Джон Демарест
Аня Кёстер
Паял Мехта
Скотт Чарльз Поттер
Диана Исабель Руиз
Деррик Райан Уитчер
Сюфэн У
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA202190530A1 publication Critical patent/EA202190530A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к агонистическим антителам к CD200R человека и их применению для лечения таких заболеваний, как атопический дерматит, хроническая спонтанная крапивница, аллергия, астма, склеродермия, синдром раздраженного кишечника (IBD), системная красная волчанка (SLE), рассеянный склероз (MS), ревматоидный артрит (RA), болезнь "трансплантат против хозяина" (GvHD) или псориаз.
EA202190530A 2018-09-14 2019-09-11 Агонистические антитела к cd200r и их применение EA202190530A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731204P 2018-09-14 2018-09-14
PCT/US2019/050511 WO2020055943A1 (en) 2018-09-14 2019-09-11 Cd200r agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA202190530A1 true EA202190530A1 (ru) 2021-06-21

Family

ID=68051977

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190530A EA202190530A1 (ru) 2018-09-14 2019-09-11 Агонистические антитела к cd200r и их применение

Country Status (26)

Country Link
US (2) US11319370B2 (ru)
EP (1) EP3849667A1 (ru)
JP (2) JP7185051B2 (ru)
KR (1) KR20210044262A (ru)
CN (1) CN112739422B (ru)
AR (1) AR116668A1 (ru)
AU (1) AU2019339334B2 (ru)
BR (1) BR112021003254A2 (ru)
CA (1) CA3112763C (ru)
CL (1) CL2021000606A1 (ru)
CO (1) CO2021003093A2 (ru)
CR (1) CR20210134A (ru)
DO (1) DOP2021000040A (ru)
EA (1) EA202190530A1 (ru)
EC (1) ECSP21017619A (ru)
IL (1) IL281442B2 (ru)
JO (1) JOP20210048A1 (ru)
MA (1) MA53604A (ru)
MX (1) MX2021003026A (ru)
MY (1) MY196156A (ru)
PE (1) PE20211742A1 (ru)
PH (1) PH12021550530A1 (ru)
SG (1) SG11202101697YA (ru)
TW (1) TWI749367B (ru)
WO (1) WO2020055943A1 (ru)
ZA (2) ZA202101246B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020368369A1 (en) 2019-10-15 2022-05-12 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
WO2023196866A1 (en) * 2022-04-06 2023-10-12 Mirobio Limited Engineered cd200r antibodies and uses thereof
CN115458048B (zh) * 2022-09-16 2023-05-26 杭州美赛生物医药科技有限公司 基于序列编解码的抗体人源化方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368535B2 (en) * 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
EP1482973B1 (en) * 2002-03-15 2009-08-19 Schering Corporation Methods of modulating cd200 receptors
CN103690947A (zh) * 2006-01-12 2014-04-02 阿莱克申药物公司 抗ox-2/cd200的抗体及其用途
CN101679519A (zh) * 2006-12-22 2010-03-24 先灵公司 Cd200r的抗体
JP6012473B2 (ja) * 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
BR112012020101A2 (pt) * 2010-02-11 2018-09-25 Alexion Pharma Inc método diagnósticos e terapêuticos usando anticorpos anti-cd200.
WO2015057906A1 (en) 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists

Also Published As

Publication number Publication date
ZA202101246B (en) 2023-04-26
CL2021000606A1 (es) 2021-09-20
TW202024132A (zh) 2020-07-01
CN112739422A (zh) 2021-04-30
SG11202101697YA (en) 2021-04-29
JP2022500080A (ja) 2022-01-04
MX2021003026A (es) 2021-05-27
WO2020055943A1 (en) 2020-03-19
AU2019339334A1 (en) 2021-03-18
PH12021550530A1 (en) 2022-02-14
JP7185051B2 (ja) 2022-12-06
MA53604A (fr) 2021-12-22
TWI749367B (zh) 2021-12-11
MY196156A (en) 2023-03-17
IL281442B2 (en) 2024-03-01
AR116668A1 (es) 2021-06-02
ECSP21017619A (es) 2021-04-29
CR20210134A (es) 2021-03-29
JP2022141959A (ja) 2022-09-29
CA3112763C (en) 2024-05-14
CN112739422B (zh) 2024-05-28
DOP2021000040A (es) 2021-03-31
AU2019339334B2 (en) 2023-03-09
PE20211742A1 (es) 2021-09-06
BR112021003254A2 (pt) 2021-05-18
US20200087395A1 (en) 2020-03-19
CA3112763A1 (en) 2020-03-19
JP7490025B2 (ja) 2024-05-24
US20220251198A1 (en) 2022-08-11
IL281442B1 (en) 2023-11-01
EP3849667A1 (en) 2021-07-21
CO2021003093A2 (es) 2021-03-19
JOP20210048A1 (ar) 2021-03-11
KR20210044262A (ko) 2021-04-22
ZA202204978B (en) 2022-09-28
IL281442A (en) 2021-04-29
US11319370B2 (en) 2022-05-03

Similar Documents

Publication Publication Date Title
EA202190530A1 (ru) Агонистические антитела к cd200r и их применение
PH12018502574A1 (en) ANTI-IgE ANTIBODIES
EA201591368A1 (ru) Антитела, связывающие ил-23
PH12016500242A1 (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
MX2021001841A (es) Anticuerpos anti-gdf15, composiciones y metodos de uso.
MX2017013080A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
GEP20207162B (en) Lag-3-binding molecules and methods of use thereof
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
BR112012021433A2 (pt) anticorpos antagonistas antirreceptor de il-7 e métodos.
EA201791590A1 (ru) Антитела к tau и их применение
JOP20210071A1 (ar) أجسام مضادة مثبّتة trem2
NZ724870A (en) Antibodies that bind human cannabinoid 1 (cb1) receptor
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
JOP20210326A1 (ar) أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
EA201691521A1 (ru) Антитела к интерлейкину-21
MX2018003982A (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano.
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
MY197821A (en) Anti-il-22r antibodies
TN2018000289A1 (en) Antibodies for il-17c
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof
EA201990493A1 (ru) Антитела к гм-ксф и их применения
GB2543729A8 (en) Antibodies to IL-24
EA202090257A1 (ru) Антитела-агонисты, которые связывают cd137 человека, и варианты их применения
EA201890629A1 (ru) Применение антител к cd40 для лечения волчаночного нефрита